KalVista Pharmaceuticals (KALV) Presents Sebetralstat Data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/6/2026
- Stocks close lower as investors eye Mideast talks, earnings
- Trump held multiple undisclosed calls with Fed Chair Warsh, reports say
- Sandisk unveils underwhelming outlook despite AI demand surge; shares slip
- Alphabet taps bond market with sweeping 10-part offering to fuel AI ambitions
- Citi says buy the pullback in memory stocks as upcycle is still in early innings
- Salesforce president Srini Tallapragada steps down, becomes advisor
- EverCommerce names Alex Goor as new CEO, founder steps down
- Sandisk (SNDK) Tops Q4 EPS by $4.66, Offers Guidance
- Crude Inventory Rose 2.5 Million Barrels Last Week - EIA
- AMD shares slide 8% after Musk flags plans to buy Nvidia chips for SpaceX
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
Leerink Partners Reiterates Outperform Rating on Kalvista Pharmaceuticals Inc (KALV)
September 6, 2024 6:35 AM EDTLeerink Partners analyst Joseph Schwartz reiterated an Outperform rating and $20.00 price target on Kalvista Pharmaceuticals Inc (NASDAQ: KALV).
The analyst comments "Bottom Line: We are updating our model following the disclosure of KALV's F1Q financial results and corporate update; the FDA recently accepted sebetralstat's NDA with a PDUFA goal date of June 17, 2025. The company continues to advance lead asset sebetralstat (KVD900), an oral plasma kallikrein inhibitor, towards a commercial launch for the on-demand treatment of... More
